EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (epinephrine) by Baxter is (α)- and beta (β)-adrenergic receptors. First approved in 2025.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
Epinephrine bitartrate in 0.9% sodium chloride is an intravenous solution containing the sympathomimetic agent epinephrine, a nonselective alpha- and beta-adrenergic agonist. It is indicated for emergency treatment of cardiovascular collapse and hypotension by stimulating myocardial contractility, increasing heart rate, and inducing peripheral vasoconstriction. This product represents a standardized IV formulation approved by the FDA in February 2025.
Early-stage post-approval product with moderate competitive pressure (30%) and growth trajectory, suggesting active commercial team expansion and market penetration initiatives.
(α)- and beta (β)-adrenergic receptors. The mechanism of the rise in blood pressure is 3-fold: a direct myocardial stimulation that increases the strength of ventricular contraction (positive inotropic action), an increased heart rate (positive chronotropic action), and peripheral vasoconstriction.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements
Worked on EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE at Baxter? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moThis product offers career opportunities primarily in hospital-focused commercial roles, supply chain management, and regulatory affairs related to IV formulation maintenance and hospital acquisition strategies. Growth-stage positioning suggests active hiring in field sales and account management, though limited clinical development reduces Medical Affairs expansion.